InSite Vision to Hold 2004 First Quarter Financial Results
Conference Call on May 14
ALAMEDA, Calif., May 11 /PRNewswire-FirstCall/ -- InSite Vision Incorporated
-- an ophthalmic therapeutics, diagnostics and drug-delivery company -- today
announced that the Company will release 2004 first quarter financial results
before market open on Friday, May 14, 2004. S. Kumar Chandrasekaran, Ph.D.,
chief executive officer, president and chief financial officer, and Sandra
Heine, senior director of finance, will host an investment-community conference
call beginning at 11:00 a.m. Eastern Time on Friday, May 14, 2004 to discuss
these results and to answer questions.
Individuals interested in listening to the conference call may do so by dialing
(888) 803-7364 for domestic callers or (706) 634-1033 for international
callers. A telephone replay will be available for 48 hours following the
conclusion of the call by dialing (800) 642-1687 (domestic) or (706) 645-9291
(international), and entering reservation code 7381658.
The live conference call will also be available via the Internet on the
investor relations section of the Company's Web site at
http://www.insitevision.com/, and a recording of the call will be available for
90 days following the completion of the call.
InSite Vision is an ophthalmic products company focused on ocular infections,
glaucoma and retinal diseases. In the area of glaucoma, the Company conducts
genomic research using TIGR and other genes. A portion of this research has
been incorporated into the Company's OcuGene(R) glaucoma genetic test for
disease management, as well as ISV-205, its novel glaucoma therapeutic.
ISV-205 uses InSite Vision's proprietary DuraSite(R) drug-delivery technology,
which also is incorporated into the ocular infection product ISV-401, and
InSite Vision's retinal disease program. Additional information can be found
at http://www.insitevision.com/.
This press release may contain, among other things, certain statements of a
forward-looking nature relating to future events or the future business
performance of InSite Vision. Such statements entail a number of risks and
uncertainties, including but not limited to: InSite Vision's ability to obtain
stockholder approval and satisfy the other conditions to closing the final
tranche of the private placement of the company's securities announced in March
2004, InSite Vision's immediate need for significant additional funding to
continue its operations beyond the middle of June 2004 in the event that it
does not consummate the final closing of the March 2004 private placement prior
to such time, the effects of its expense control activities on its operations
and product development; its ability to obtain regulatory approval and market
acceptance of its products, including its OcuGene(R) glaucoma genetic test,
ISV-401 and ISV-205; InSite Vision's ability to maintain and develop additional
collaborations and commercial agreements with corporate partners, including
those with respect to ISV-401 and ISV-205; its reliance on third parties for
the development, marketing and sale of its products; the initiation and results
of preclinical and clinical studies; its ability to adequately protect its
intellectual property; and determinations by the U.S. Food and Drug
Administration, including those with respect to OcuGene, ISV-401 and ISV-205.
Reference is made to the discussion of risk factors detailed in InSite Vision's
filings with the Securities and Exchange Commission, including its annual
report on Form 10-K for the fiscal year ended December 31, 2003 and the
Company's subsequent quarterly reports on Form 10-Q. Any projections in this
release are based on limited information currently available to InSite Vision,
which is subject to change. Although any such projections and the factors
influencing them will likely change, InSite Vision undertakes no obligation to
update the information. Such information speaks only as of the date of this
release. Actual events or results could differ materially and no reader of
this release should assume later that the information provided today is still
valid.
Note to Editors: OcuGene is written with a "small cap" G; if doing so is not
possible, please use an upper case G. InSite Vision Incorporated, InSite
Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual
property of their respective owners.
For further information, please contact: S. Kumar Chandrasekaran, CEO, or
Sandra Heine, Director of Finance, both of InSite Vision Incorporated,
+1-510-865-8800; or investors, Bruce Voss, , or Jody Cain, , both of
Lippert/Heilshorn & Associates, +1-310-691-7100, for InSite Vision, or media,
Chenoa Taitt, , or Michael Hopkins, , both of Lippert/Heilshorn & Associates,
+1-212-838-3777, for InSite Vision Incorporated. DATASOURCE: InSite Vision Incorporated CONTACT: S. Kumar Chandrasekaran, CEO, or Sandra Heine, Director of Finance, both of InSite Vision Incorporated, +1-510-865-8800; or investors, Bruce Voss, , or Jody Cain, , both of Lippert/Heilshorn & Associates, +1-310-691-7100, for InSite Vision, or media, Chenoa Taitt, , or Michael Hopkins, , both of Lippert/Heilshorn & Associates, +1-212-838-3777, for InSite Vision Incorporated Web site: http://www.insitevision.com/
|